You can buy or sell CALA and other stocks, options, ETFs, and crypto commission-free!
Calithera Biosciences, Inc. engages in discovering and developing small molecule drugs that that target novel and critical metabolic pathway in tumor and cance-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. Read More The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Seeking AlphaMay 9
Calithera Biosciences, Inc. CEO Susan Molineaux on Q1 2019 Results - Earnings Call Transcript
Calithera Biosciences, Inc. (NASDAQ:CALA) Q1 2019 Results Earnings Conference Call May 9, 2019 5:00 PM ET Company Participants Jennifer McNealey - Vice President of Investor Relations and Strategy Susan Molineaux - Founder, President, Chief Executive Officer Keith Orford - Chief Medical Officer Stephanie Wong - Senior Vice President of Finance and Secretary Conference Call Participants John Barrett - SVB Leerink Matt Phipps - William Blair Operator Hello and welcome to the Calithera Biosciences Q1...
Yahoo FinanceMay 9
Calithera Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights
--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on May 9, 2019-- SOUTH SAN FRANCISCO, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (CALA), a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways, announced today its financial results for the first quarter ended March 31, 2019. As of March 31, 2019, cash equivalents and investments totaled $117.0 million...
-$0.44 per share
-$0.61 per share